Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05216302
Other study ID # IIBSP-PRO-2021-10
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date November 1, 2023

Study information

Verified date July 2023
Source Universitat Pompeu Fabra
Contact Anabel Casanovas Álvarez, MSc
Phone +34931696573
Email acasanovasa@tecnocampus.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prehabilitation for women diagnosed with breast cancer is commonly not part of the clinical pathways as little time (usually a few days) is left between diagnosis and surgery. However, a great proportion of these patients will undergo neoadjuvant chemotherapy which provides a window opportunity to improve patients' physical status to withstand surgery and minimize post-operative musculoskeletal complications associated with surgery. To this end, the aim of this study is to assess the efficacy of a prehabilitation program consisting of health education and a supervised nordic walking-based intervention in women diagnosed with breast cancer currently undergoing neoadjuvant chemotherapy to decrease post-operative musculoskeletal impairments and improve functionality of the affected arm. The study is an open-label, single-blind randomised controlled trial conducted at one tertiary hospital. Women diagnosed with breast cancer scheduled for surgery and currently undergoing chemotherapy will be randomised to either usual care (UC) or prehabilitation (PREHAB). Patients will be assessed for eligibility during the fourth out of six course of chemotherapy. Those randomised to the PREHAB group will participate in a supervised group-based nordic walking intervention twice weekly during 8 weeks (approximately 16 sessions). In addition, participants will receive written information regarding the benefits of exercise during cancer treatment and surveillance. Patients will be assessed prior to surgery as well as at 1, 3 and 6 months postoperatively.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date November 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of breast cancer scheduled for surgery with or without lymphadenectomy - Candidates to receive neoadjuvant chemotherapy - Not currently undergoing any other physical therapy therapies or treatments Exclusion Criteria: - Cognitive impairment or inability to read Catalan or Spanish - Prior diagnosis of shoulder impairment or injury - Major musculoskeletal, neurological or cardiorespiratory limitations to prevent participation in the exercise program

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Group-based Nordic Walking Exercise Program
An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.

Locations

Country Name City State
Spain Hospital Santa Creu i Sant Pau Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Raquel Sebio Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

References & Publications (5)

ILokapavani Y, Krishna SR, Madhavi K. nfluence of Pre - Operative Physical Therapy Education and Exercise on Post-operative Shoulder Range of Motion and Functional Activites in Subjects with Modified Radical Mastectomy. Int J Physiother 2014. DOI: 10.15621/ijphy/2014/v1i4/54556

McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006 Jul 4;175(1):34-41. doi: 10.1503/cmaj.051073. — View Citation

Santa Mina D, Brahmbhatt P, Lopez C, Baima J, Gillis C, Trachtenberg L, Silver JK. The Case for Prehabilitation Prior to Breast Cancer Treatment. PM R. 2017 Sep;9(9S2):S305-S316. doi: 10.1016/j.pmrj.2017.08.402. — View Citation

Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013 Aug;92(8):715-27. doi: 10.1097/PHM.0b013e31829b4afe. — View Citation

Yang A, Sokolof J, Gulati A. The effect of preoperative exercise on upper extremity recovery following breast cancer surgery: a systematic review. Int J Rehabil Res. 2018 Sep;41(3):189-196. doi: 10.1097/MRR.0000000000000288. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH) Functionality of the affected upper arm using the DASH questionnaire. The questionnaire compromises 11 items. Scoring ranges from 0 (no disability) to 100 (more severe disability) Pre-Surgery (one week)
Primary Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH) Functionality of the affected upper arm using the DASH questionnaire. The questionnaire compromises 11 items. Scoring ranges from 0 (no disability) to 100 (more severe disability) One month post-surgery
Primary Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH) Functionality of the affected upper arm using the DASH questionnaire. The questionnaire compromises 11 items. Scoring ranges from 0 (no disability) to 100 (more severe disability) Three months post-surgery
Primary Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH) Functionality of the affected upper arm using the DASH questionnaire. The questionnaire compromises 11 items. Scoring ranges from 0 (no disability) to 100 (more severe disability) Six months post-surgery
Secondary Upper arm volume Perimeter of the affected arm will be measured with a tape measure at hand, wrist, elbow and shoulder level Pre-Surgery (one week)
Secondary Upper arm volume Perimeter of the affected arm will be measured with a tape measure at hand, wrist, elbow and shoulder level One month post-surgery
Secondary Upper arm volume Perimeter of the affected arm will be measured with a tape measure at hand, wrist, elbow and shoulder level Three months post-surgery
Secondary Upper arm volume Perimeter of the affected arm will be measured with a tape measure at hand, wrist, elbow and shoulder level Six months post-surgery
Secondary Range of Movement (ROM) Range of movement of the affected arm in three axes using a goniometer Pre-Surgery (one week)
Secondary Range of Movement (ROM) Range of movement of the affected arm in three axes using a goniometer One month post-surgery
Secondary Range of Movement (ROM) Range of movement of the affected arm in three axes using a goniometer Three months post-surgery
Secondary Range of Movement (ROM) Range of movement of the affected arm in three axes using a goniometer Six months post-surgery
Secondary Pain severity Global pain assessed with a Visual Analog Scale (0 no pain to 10 maximum pain) Pre-Surgery (one week)
Secondary Pain severity Global pain assessed with a Visual Analog Scale (0 no pain to 10 maximum pain) One month post-surgery
Secondary Pain severity Global pain assessed with a Visual Analog Scale (0 no pain to 10 maximum pain) Three months post-surgery
Secondary Pain severity Global pain assessed with a Visual Analog Scale (0 no pain to 10 maximum pain) Six months post-surgery
Secondary Health-Related Quality of Life Health-Related Quality of Life will be assessed with the questionnaire developed by the European Organization for Research and Treatment (EORTC) Quality of Life (QLQ) questionnaire (EORTC QLQ C30). Scores range from 0 to 100 with higher values associated with better overall quality of life Pre-Surgery (one week)
Secondary Health-Related Quality of Life Health-Related Quality of Life will be assessed with the questionnaire developed by the European Organization for Research and Treatment (EORTC) Quality of Life (QLQ) questionnaire (EORTC QLQ C30). Scores range from 0 to 100 with higher values associated with better overall quality of life One month post-surgery
Secondary Health-Related Quality of Life HHealth-Related Quality of Life will be assessed with the questionnaire developed by the European Organization for Research and Treatment (EORTC) Quality of Life (QLQ) questionnaire (EORTC QLQ C30). Scores range from 0 to 100 with higher values associated with better overall quality of life Three months post-surgery
Secondary Health-Related Quality of Life Health-Related Quality of Life will be assessed with the questionnaire developed by the European Organization for Research and Treatment (EORTC) Quality of Life (QLQ) questionnaire (EORTC QLQ C30). Scores range from 0 to 100 with higher values associated with better overall quality of life Six months post-surgery
Secondary Handgrip Strength Handgrip strength will be determined using an hydraulic dynamometer (Jamar). Both hands will be assessed and the better result out of three attempts will be used. Pre-Surgery (one week)
Secondary Handgrip Strength Handgrip strength will be determined using an hydraulic dynamometer (Jamar). Both hands will be assessed and the better result out of three attempts will be used. One month post-surgery
Secondary Handgrip Strength Handgrip strength will be determined using an hydraulic dynamometer (Jamar). Both hands will be assessed and the better result out of three attempts will be used. Three months post-surgery
Secondary Handgrip Strength Handgrip strength will be determined using an hydraulic dynamometer (Jamar). Both hands will be assessed and the better result out of three attempts will be used. Six months post-surgery
Secondary Functional capacity Functional capacity will be measured with the distance covered by the 6-Minute Walk Test. Pre-surgery (one week)
Secondary Functional capacity Functional capacity will be measured with the distance covered by the 6-Minute Walk Test. One month post-surgery
Secondary Functional capacity Functional capacity will be measured with the distance covered by the 6-Minute Walk Test. Three months post-surgery
Secondary Functional capacity Functional capacity will be measured with the distance covered by the 6-Minute Walk Test. Six months post-surgery
Secondary Adherence Adherence to the scheduled sessions will be registered in the Prehab group and will be reported as percentage of attended vs. scheduled. Pre-Surgery (one week)
Secondary Physical Activity Physical activity levels will be measured using the short form of the International Physical Activity Questionnaire (IPAQ). Estimated METS per week will be calculated based on the available formulas. Pre-surgery (one week)
Secondary Physical Activity Physical activity levels will be measured using the short form of the International Physical Activity Questionnaire (IPAQ). Estimated METS per week will be calculated based on the available formulas. One month post-surgery
Secondary Physical Activity Physical activity levels will be measured using the short form of the International Physical Activity Questionnaire (IPAQ). Estimated METS per week will be calculated based on the available formulas. Three months post-surgery
Secondary Physical Activity Physical activity levels will be measured using the short form of the International Physical Activity Questionnaire (IPAQ). Estimated METS per week will be calculated based on the available formulas. Six months post-surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2